Jason Lamar Aldred
About
Dr. Jason Aldred is a board-certified neurologist based in Spokane, Washington, where he practices at Selkirk Neurology. His clinical work centers on movement disorders, with a particular focus on Parkinson's disease, and he directs the Selkirk Neurology HDSA Center of Excellence Partner Site affiliated with the University of Washington, which serves patients with Huntington's disease.
His research activity is extensive, spanning more than 50 peer-reviewed publications in journals including Nature Medicine, Neurology and Therapy, and Movement Disorders Clinical Practice. His published work addresses advanced Parkinson's disease therapies, including continuous subcutaneous foslevodopa/foscarbidopa infusion, deep brain stimulation programming, LRRK2-targeting antisense oligonucleotides, and genetic testing in the context of gene-targeted clinical trials. He has contributed to both phase 1 and phase 3 trial investigations, reflecting sustained involvement in clinical research alongside his practice.
Dr. Aldred holds licensure in Washington, Oregon, and Wisconsin.
Credentials
Publications
- Foslevodopa/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation.
- LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
- Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials.
- Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.
- Sustained Therapeutic Benefits Using Image-Guided Programming at Activation of Deep Brain Stimulation for Parkinson's Disease.
- Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.
- Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
- Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.
- Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
- Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Request CV and rates
Tell us about your case and we'll connect you with Jason Lamar Aldred within two business days.
Other Neurology experts
Verified specialists available for your case.
